Form 4: Eli Lilly Executive Donald A. Zakrowski Reports Stock Transactions

Eli Lilly's SVP, Finance, & CAO, Donald A. Zakrowski, reported acquiring 1,254 shares of common stock and holding 1,708 shares indirectly through a 401(k).

Summary

• Donald A. Zakrowski, SVP, Finance, & CAO at Eli Lilly & Co, reported a transaction involving the company's common stock.
• On February 12, 2024, Mr. Zakrowski acquired 1,254 shares of common stock at a price of $737.26 per share.
• Following this transaction, Mr. Zakrowski directly owns 8,630 shares of common stock.
• He also indirectly owns 1,708 shares through a 401(k) plan.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing and does not indicate any positive or negative sentiment. It is a neutral transaction.

Industry Context

This is a routine filing related to insider trading regulations, and is common for executives at publicly traded companies.

Comparison to Industry Standards

• Form 4 filings are standard practice for corporate insiders at all publicly traded companies in the US, including competitors such as Pfizer (PFE) and Johnson & Johnson (JNJ).
• The reporting requirements are consistent across the industry, ensuring transparency in executive stock transactions.
• The volume of shares traded is not unusual for an executive at this level.

Stakeholder Impact

• The transaction has a minimal impact on stakeholders as it is a routine executive stock purchase.

Key Dates

Keywords

Eli Lilly, LLY, stock transaction, insider trading, Form 4, Donald A. Zakrowski, executive compensation, share acquisition